floxuridine has been researched along with Hepatitis B in 2 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
Excerpt | Relevance | Reference |
---|---|---|
"To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival." | 9.07 | Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994) |
"To conduct a pilot trial of hepatic arterial infusion (HAI) of floxuridine (FUDR), leucovorin, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (FLAP) in nonresectable hepatocellular cancer (HCC) confined to the liver and assess the effects of hepatitis B (HBV) and hepatitis C (HCV) viral markers on toxicity, response to treatment, and patient survival." | 5.07 | Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. ( Carrasco, H; Charnsangavej, C; Chase, J; Chuang, V; Fischer, H; Lawrence, D; Patt, YZ; Roh, M; Smith, R; Yoffe, B, 1994) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fiume, L | 1 |
Busi, C | 1 |
Mattioli, A | 1 |
Patt, YZ | 1 |
Charnsangavej, C | 1 |
Yoffe, B | 1 |
Smith, R | 1 |
Lawrence, D | 1 |
Chuang, V | 1 |
Carrasco, H | 1 |
Roh, M | 1 |
Chase, J | 1 |
Fischer, H | 1 |
1 review available for floxuridine and Hepatitis B
Article | Year |
---|---|
Targeting of antiviral drugs by coupling with protein carriers.
Topics: Albumins; alpha-Fetoproteins; Amanitins; Amino Sugars; Animals; Antiviral Agents; Asialoglycoprotein | 1983 |
1 trial available for floxuridine and Hepatitis B
Article | Year |
---|---|
Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 1994 |